Table 4.
Changes in markers of insulin resistance and inflammation in women with metabolic syndrome after agraz consumption compared to placebo.
| Variables | Placebo | Agraz | Δ (Agraz-Placebo) | p | ||
|---|---|---|---|---|---|---|
| n | Mean or Median ± SD or IQR (p25-p75) | n | Mean or Median ± SD or IQR (p25-p75) | Mean or Median ± SD or IQR (p25-p75) | ||
| Insulin (mUI/L) b | 39 | 16.34 (13.03) | 39 | 15.0 (14.01) | 0.26 (4.91) | 0.922 |
| HOMA 2 index b | 38 | 2.33 (1.83) | 40 | 2.21 (1.8) | 0.02 (0.66) | 0.577 |
| QUICKI index a | 39 | 0.314 ± 0.024 | 39 | 0.315 ± 0.024 | 0.0 ± 0.012 | 0.714 |
| hs-CRP (mg/L) b | 37 | 4.8 (2.81) | 37 | 3.75 (2.80) | −0.54 (2.5) | 0.103 |
| Adiponectin (ug/mL) b | 37 | 12.75 (14.53) | 37 | 13.23 (11.38) | 0.89 (4.43) | 0.225 |
| Resistin (ng/mL) a | 38 | 31.96 ± 7.77 | 38 | 33.84 ± 10.1 | 1.88 ± 9.45 | 0.229 |
| Leptin (ng/mL) a | 38 | 3.58 ± 1.52 | 38 | 3.58 ± 1.66 | 0.025 ± 0.76 | 0.986 |
a Paired T; b Wilcoxon; SD: Standard deviation; IQR: Interquartile range; Significance p ≤ 0.05. hs-CRP: high-sensitive C-reactive protein.